These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29246162)

  • 1. Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
    Curtis JR; Winthrop K; O'Brien C; Ndlovu MN; de Longueville M; Haraoui B
    Arthritis Res Ther; 2017 Dec; 19(1):276. PubMed ID: 29246162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
    Bykerk VP; Cush J; Winthrop K; Calabrese L; Lortholary O; de Longueville M; van Vollenhoven R; Mariette X
    Ann Rheum Dis; 2015 Jan; 74(1):96-103. PubMed ID: 24092417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
    Harrold LR; Litman HJ; Saunders KC; Dandreo KJ; Gershenson B; Greenberg JD; Low R; Stark J; Suruki R; Jaganathan S; Kremer JM; Yassine M
    Arthritis Res Ther; 2018 Jan; 20(1):2. PubMed ID: 29329557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
    Tanaka Y; Takeuchi T; Haaland D; Hall S; Inanc N; Li Z; Xavier RM; Cara C; Tilt N; Taylor PC
    Int J Rheum Dis; 2023 Jul; 26(7):1248-1259. PubMed ID: 37195063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
    Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
    RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data.
    Lau CS; Chen YH; Lim K; de Longueville M; Arendt C; Winthrop K
    Clin Rheumatol; 2021 Mar; 40(3):867-875. PubMed ID: 32740672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
    Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
    Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: Interim analysis of post-marketing surveillance].
    Kameda H; Nishida K; Nannki T; Watanabe A; Oshima Y; Momohara S
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(3):196-205. PubMed ID: 28747607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis.
    Tanaka Y; Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Int J Rheum Dis; 2020 Mar; 23(3):316-324. PubMed ID: 31957303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
    Curtis JR; Herrem C; Ndlovu 'N; O'Brien C; Yazici Y
    Arthritis Res Ther; 2017 Sep; 19(1):215. PubMed ID: 28962590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E; Landewé R; van Vollenhoven R; Combe B; Strand V; Mease P; Shaughnessy L; VanLunen B; van der Heijde D
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Certolizumab Pegol, Abatacept, and Biosimilar Infliximab in Patients With Rheumatoid Arthritis Treated in Routine Care: Observational Data From the Danish DANBIO Registry Emulating a Randomized Trial.
    Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Bjørner JB; Hetland ML
    Arthritis Rheumatol; 2019 Dec; 71(12):1997-2004. PubMed ID: 31268624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.